Avalo Therapeutics has acquired 1 company.
Avalo Therapeutics’ largest acquisition to date was in 2019, when it acquired Aevi Genomic Medicine for $23M. Avalo Therapeutics has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
540 Gaither Road, Suite 400,
Rockville, Maryland
20850
United States,
(410) 522-8707
www.avalotx.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2019-12-05 |
Aevi Genomic Medicine, Inc. · Life Science
Wayne, Pennsylvania · www.aevigenomics.com Aevi Genomic Medicine, Inc. is a biopharmaceutical company developing a technology platform for the purpose of treating patients with rare and orphan diseases. Driven by a commitment to patients with pediatric-onset life-altering diseases, Aevi’s research and development efforts include working with the Center for Applied Genomics (CAG) at Children’s Hospital of Philadelphia to leverage novel genetic discoveries to progress its genomic medicine strategy. Aevi Genomic Medicine was founded in 2000 and is based in Wayne, Pennsylvania. Advisors: Troutman Pepper Hamilton Sanders , Wedbush Securities |
23 | Add-on Acquisition |
Avalo Therapeutics
|
- |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
